EUCTR2005-004623-19-NL进行中（未招募）不适用
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis - Oral R115866 psoriasis dose ranging study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 192
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject has completed an appropriately administered informed consent
- •Subject is at least 18 years old
- •Subject is a male or is a women who is NOT of childbearing potential
- •Subject has plaque psoriasis that is appropriate for treatment with the study medication covering =10% BSA
- •Subject has a PASI score =10.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subject has a history of sensitivity to any of the ingredients in the study medication
- •Subject is currently participating in, or has within the 30 days prior to the clinical trial participated in an investigational clinical trial.
研究者
相似试验
尚未招募
2 期
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque PsoriasisNL-OMON30076Synergie/ Ilse pharma consultancy37
进行中（未招募）
不适用
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis - Oral R115866 psoriasis dose ranging studyTreatment of Plaque PsoriasisEUCTR2005-004623-19-IEBarrier Therapeutics, Inc.192
进行中（未招募）
1 期
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis - Oral R115866 psoriasis dose ranging studyTreatment of Plaque PsoriasisEUCTR2005-004623-19-GBBarrier Therapeutics, Inc.
进行中（未招募）
1 期
A Study to Assess Safety, Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsEbolaMedDRA version: 20.0 Level: PT Classification code 10014071 Term: Ebola disease System Organ Class: 10021881 - Infections and infestationsEUCTR2015-000596-27-GBJanssen Vaccines & Prevention BV421
终止
1 期
A Phase 1/2 randomized, placebo-controlled, multi-centre study to evaluate the safety and immunogenicity of a novel Receptor Binding Domain (RBD) COVID-19 Vaccine in Healthy AdultsSARS-CoV-2COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620001308987Accelagen Pty Ltd35